Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Feb 27, 2025
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025
Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025
Read more at globenewswire.com
